[1] |
World Health Organization. WHO Coronavirus (COVID-19) dashboard. https://covid19.who.int. [2021-09-09]. |
[2] |
Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 2020; 382, 1708−20. doi: 10.1056/NEJMoa2002032 |
[3] |
Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA, 2020; 323, 1824−36. doi: 10.1001/jama.2020.6019. |
[4] |
Wang DW, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA, 2020; 323, 1061−9. doi: 10.1001/jama.2020.1585 |
[5] |
Cao B, Wang YM, Wen DN, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe COVID-19. N Engl J Med, 2020; 382, 1787−99. doi: 10.1056/NEJMoa2001282 |
[6] |
Elfiky AA. Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study. Life Sci, 2020; 253, 117592. doi: 10.1016/j.lfs.2020.117592 |
[7] |
Beck BR, Shin B, Choi Y, et al. Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model. Comput Struct Biotechnol J, 2020; 18, 784−90. doi: 10.1016/j.csbj.2020.03.025 |
[8] |
Prokunina-Olsson L, Alphonse N, Dickenson RE, et al. COVID-19 and emerging viral infections: the case for interferon lambda. J Exp Med, 2020; 217, e20200653. doi: 10.1084/jem.20200653 |
[9] |
Zhou F, Yu T, Du RH, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 2020; 395, 1054−62. doi: 10.1016/S0140-6736(20)30566-3 |
[10] |
Li H, Liu L, Zhang DY, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet, 2020; 395, 1517−20. doi: 10.1016/S0140-6736(20)30920-X |